CoChat
Sign Up
Cited by 449Diabetes and associated disordersDiabetes Management and ResearchPancreatic function and diabetes

The DOI matches its Crossref record, with a small difference in title or year; 30 of the 30 references it cites were found in a registry or an index.

CYCLOSPORIN INCREASES THE RATE AND LENGTH OF REMISSIONS IN INSULIN-DEPENDENT DIABETES OF RECENT ONSET

Feutren, G, Assan, R, Karsenty, G, Du Rostu, H, Sirmai, J, Papoz, L, Vialettes, B, Vexiau, P, Rodier, M, Lallemand, A, Bach, J.-F·1986·The Lancet
DOI 10.1016/s0140-6736(86)91943-4
Open this paper in CoChat — free account

Abstract

In a double-blind trial 122 patients aged 15-40 years with insulin-dependent diabetes of recent onset were randomly assigned to cyclosporin 7.5 mg/kg per day or placebo. At the sixth month 25.4% of the cyclosporin group and 18.6% of the placebo group were in complete remission (not a significant difference). Treatment was continued in those patients with complete or partial remission (insulin requirement less than 0.25 U/kg per day) and 106 patients were followed to nine months, at which stage 24.1% of the original cyclosporin group and 5.8% of the original placebo group were in complete remission (p less than 0.01). For those patients whose whole-blood trough cyclosporin levels in the first three months averaged 300 ng/ml or more, the rates of complete remission at six and nine months were 37.5% and 37%. The rates of partial remission were also higher in the cyclosporin group and at six months the rate of complete or partial remission was 46% in the whole cyclosporin group and 65.6% in those with an average blood level exceeding 300 ng/ml in the first three months, versus 28.8% in the placebo group. The principal side-effect of cyclosporin was a modest and reversible increase in plasma creatinine. These results indicate that cyclosporin promotes the remission of type I diabetes and suggest the need for new controlled protocols aimed at evaluating the length of the effect and selecting the best drug regimen.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(86)91943-4

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ciclosporin did not produce lasting remission, although insulin needs fell while patients were on it.

    “Although ciclosporin was unable to induce a durable disease remission, insulin requirements of patients decreased during active treatment, generating enthusiasm that immune modulation could treat type 1 diabetes.134–136”

    From Type 1 diabetes (2018) · cites this paper as [136]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. G. Feutren, Mc Quiniou-Debrie, M. Debray-Sachs, et al., Immunological effects of cyclosporine A in type 1 diabetes mellitus, Transplant Proc ((in press)).
  2. 1985, WHO Tech Rep Ser

Cited by

Sorted by citations

Related

Metadata

Authors
Feutren, G., Assan, R., Karsenty, G., Du Rostu, H., Sirmai, J., Papoz, L., Vialettes, B., Vexiau, P., Rodier, M., Lallemand, A., & Bach, J.-F.
Affiliations
Hôpital Necker-Enfants Malades (FR)
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
1986-07
Volume
328
Issue
8499
Pages
119-124
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(86)91943-4
OpenAlex
W2150631622
Cited by
448
References
28
Citations by year
2026: 2 · 2025: 10 · 2024: 9 · 2023: 7 · 2022: 9 · 2021: 11 · 2020: 3 · 2019: 5 · 2018: 7 · 2017: 2 · 2016: 11 · 2015: 11 · 2014: 8 · 2013: 18 · 2012: 10
FWCI
20.67
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
cyclosporine, type 1 diabetes, recent-onset diabetes, remission, partial remission, serum creatinine, adverse drug reactions, immunosuppressive therapy
MeSH terms
Administration, Oral, Adolescent, Adult, Bacterial Infections, Clinical Trials as Topic, Cyclosporins, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypertension, Hypertrichosis, Insulin, Kidney Function Tests, Male, Random Allocation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review